109 related articles for article (PubMed ID: 7569017)
1. The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors.
Van den Bogaert W; van der Schueren E; Horiot JC; De Vilhena M; Schraub S; Svoboda V; Arcangeli G; de Pauw M; van Glabbeke M
Radiother Oncol; 1995 May; 35(2):100-6. PubMed ID: 7569017
[TBL] [Abstract][Full Text] [Related]
2. Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer.
van den Bogaert W; van der Schueren E; Horiot JC; Chaplain G; Devilhena M; Raposo S; Leonor J; Schraub S; Chenal C; Barthelme E
Int J Radiat Oncol Biol Phys; 1986 Apr; 12(4):587-91. PubMed ID: 3516953
[TBL] [Abstract][Full Text] [Related]
3. The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.
Van den Bogaert W; van der Schueren E; Horiot JC; De Vilhena M; Schraub S; Svoboda V; Arcangeli G; de Pauw M; Van Glabbeke M
Radiother Oncol; 1995 May; 35(2):91-9. PubMed ID: 7569030
[TBL] [Abstract][Full Text] [Related]
4. Late results of multiple fractions per day (MFD) with misonidazole in advanced cancer of the head and neck. A pilot study of the EORTC radiotherapy group.
Van den Bogaert W; van der Schueren E; Van Tongelen C; Horiot JC; Chaplain G; Arcangeli G; Gonzalez D; Svoboda V
Radiother Oncol; 1985 Feb; 3(2):139-44. PubMed ID: 3983422
[TBL] [Abstract][Full Text] [Related]
5. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck.
Fazekas J; Pajak TF; Wasserman T; Marcial V; Davis L; Kramer S; Rotman M; Stetz J
Int J Radiat Oncol Biol Phys; 1987 Aug; 13(8):1155-60. PubMed ID: 3301758
[TBL] [Abstract][Full Text] [Related]
6. Irradiation with misonidazole and hyperbaric oxygen: final report on a randomized trial in advanced head and neck cancer.
Sealy R; Cridland S; Barry L; Norris R
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1343-6. PubMed ID: 3531113
[TBL] [Abstract][Full Text] [Related]
7. Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial.
Bartelink H; Van den Bogaert W; Horiot JC; Jager J; van Glabbeke M
Eur J Cancer; 2002 Mar; 38(5):667-73. PubMed ID: 11916549
[TBL] [Abstract][Full Text] [Related]
8. The feasibility of high-dose multiple daily fractionation and its combination with anoxic cell sensitizers in the treatment of head and neck cancer. A pilot study of the Radiotherapy Group of the EORTC (European Organisation for Research on Treatment of Cancer).
Van den Bogaert W; van der Schueren E; Horiot JC; Chaplain G; Arcangeli G; Gonzalez D; Svoboda V
Int J Radiat Oncol Biol Phys; 1982 Oct; 8(10):1649-55. PubMed ID: 7153077
[TBL] [Abstract][Full Text] [Related]
9. Hyperfractionated radiotherapy with or without misonidazole: results of a prospective randomized study in stage III-IV squamous cell carcinoma of the head and neck.
Panis X; Nguyen TD; Froissart D; Demange L
Int J Radiat Oncol Biol Phys; 1984 Oct; 10(10):1845-9. PubMed ID: 6386760
[TBL] [Abstract][Full Text] [Related]
10. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27.
Lee WR; Berkey B; Marcial V; Fu KK; Cooper JS; Vikram B; Coia LR; Rotman M; Ortiz H
Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):1069-75. PubMed ID: 9869231
[TBL] [Abstract][Full Text] [Related]
11. The treatment of locally advanced head and neck cancer with misonidazole, hyperbaric oxygen and irradiation: an interim report.
Sealy R; Cridland S
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1721-3. PubMed ID: 6384161
[TBL] [Abstract][Full Text] [Related]
12. Does initial haemoglobin level modify the efficacy of radiosensitizers? An analysis of the MRC misonidazole studies in head and neck cancer and cervix cancer.
Freedman LS; Honess DJ; Bleehen NM; Adams GE; Dische S; Henk JM
Int J Radiat Biol Relat Stud Phys Chem Med; 1987 Dec; 52(6):965-7. PubMed ID: 3500934
[No Abstract] [Full Text] [Related]
13. Cisplatin as a radiation sensitizer in the treatment of advanced head and neck cancers. Results of a phase II study.
Chougule PB; Suk S; Chu QD; Leone L; Nigri PT; McRae R; Lekas M; Barone A; Bhat D; Bellino J
Cancer; 1994 Oct; 74(7):1927-32. PubMed ID: 8082098
[TBL] [Abstract][Full Text] [Related]
14. A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of head and neck cancer. MRC working party on misonidazole in head and neck cancer.
Br J Radiol; 1984 Jul; 57(679):585-95. PubMed ID: 6329395
[TBL] [Abstract][Full Text] [Related]
15. The use of misonidazole in association with a three-fractions per day regimen in advanced head and neck epidermoid cancer. A pilot study.
Awwad HK; Barsoum M; El Merzabani M; Omar S; El Badawy S; Ezzat S; El Baki HA; Zaki A
Am J Clin Oncol; 1983 Feb; 6(1):91-7. PubMed ID: 6301258
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04).
Lee DJ; Pajak TF; Stetz J; Order SE; Weissberg JB; Fischer JJ
Int J Radiat Oncol Biol Phys; 1989 Feb; 16(2):465-70. PubMed ID: 2646255
[TBL] [Abstract][Full Text] [Related]
17. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
18. Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume.
Chufal KS; Rastogi M; Srivastava M; Pant MC; Bhatt ML; Srivastava K
Jpn J Clin Oncol; 2006 Sep; 36(9):537-46. PubMed ID: 16905755
[TBL] [Abstract][Full Text] [Related]
19. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
Ghadjar P; Simcock M; Studer G; Allal AS; Ozsahin M; Bernier J; Töpfer M; Zimmermann F; Betz M; Glanzmann C; Aebersold DM;
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):524-31. PubMed ID: 21300466
[TBL] [Abstract][Full Text] [Related]
20. Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer.
Fu KK; Cooper JS; Marcial VA; Laramore GE; Pajak TF; Jacobs J; Al-Sarraf M; Forastiere AA; Cox JD
Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):425-38. PubMed ID: 8655364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
